Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapid Dose TherapeuticsRDTCF -7.61%29 PS Ratio is 4.53 as of Jul. 14, 2026, which is 73% below its 10-year median of 16.90. GuruFocus rates RDTCF with a GF Score™ of 29/100 and a GF Value™ of $0.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Rapid Dose Therapeutics ranks better than 63.87% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Rapid Dose Therapeutics's share price is $0.0725.
Rapid Dose Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was $0.02. Hence, Rapid Dose Therapeutics's PS Ratio for today is 4.53.
The historical rank and industry rank for Rapid Dose Therapeutics's PS Ratio or its related term are showing as below:
RDTCF'
s PS Ratio Range Over the Past 10 Years
Min: 4.29 Med: 16.9 Max: 350
Current: 5.06
During the past 13 years, Rapid Dose Therapeutics's highest PS Ratio was 350.00. The lowest was 4.29. And the median was 16.90.
RDTCF's PS Ratio is ranked better than 63.87% of 930
companies
in the Biotechnology industry
Industry Median: 9.405
vs RDTCF: 5.06
During the past 13 years, Rapid Dose Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 91.30% per year. The lowest was -2.00% per year. And the median was 22.10% per year.
Back to Basics: PS Ratio
Rapid Dose Therapeutics (OTCPK:RDTCF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rapid Dose Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Rapid Dose Therapeutics's Share Price of today is $0.0725. Rapid Dose Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Rapid Dose Therapeutics (RDTCF) has a PS Ratio of 4.53 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Rapid Dose Therapeutics and its competitors. This is 73% below median its historical median of 16.90. Over the past decade, Rapid Dose Therapeutics' PS Ratio has ranged from 4.29 to 350.00. According to the industry distribution chart, Rapid Dose Therapeutics ranks #336 out of 930 companies in the Biotechnology industry, placing it in the top 36.1%.
Is Rapid Dose Therapeutics' PS Ratio too high?
Rapid Dose Therapeutics' current PS Ratio of 4.53 is 73% below median its 10-year median of 16.90. Over the past 10 years, this metric has ranged from a low of 4.29 to a high of 350.00. The Biotechnology industry median PS Ratio is 9.41. Rapid Dose Therapeutics' value of 4.53 is 51.8% below this industry median. Based on the distribution chart, Rapid Dose Therapeutics ranks #336 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rapid Dose Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #336 out of 930 companies for PS Ratio. This puts Rapid Dose Therapeutics in the upper half of its industry. The industry median PS Ratio is 9.41. Rapid Dose Therapeutics' value of 4.53 is 51.8% below this benchmark. Historically, Rapid Dose Therapeutics' own PS Ratio has ranged from 4.29 to 350.00 over the past decade. While the company's 10-year median is 16.90 vs. the industry median of 9.41, Rapid Dose Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Dose Therapeutics's current PS Ratio of 4.53 is 51.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Rapid Dose Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Dose Therapeutics's current PS Ratio is 4.53, which is 73% below median its own 10-year median of 16.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.22, compared to a current price of $0.07 — trading 67% below its estimated fair value. The current PS Ratio is 4.53, which is 73% below median its 10-year median of 16.90 and 51.8% below the Biotechnology industry median of 9.41. Rapid Dose Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current PS Ratio is 4.53 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued.
The current stock price of $0.07 is trading 67% below its estimated GF Value™ of $0.22.
GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.
Key valuation signals for RDTCF:
PS Ratio: 4.53 (73% below median its 10-year median of 16.90)
GF Value™: $0.22 vs. price of $0.07 (67% below fair value)
Industry Position: 51.8% below the Biotechnology median (#336 of 930)
No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
29GF Score
Get the complete analysis for RDTCF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
